Navigation Links
New discovery prevents symptoms of rare genetic disorder
Date:12/2/2010

A new study offers hope for children born with a rare genetic disease, according to a paper published by the American Association for the Advancement of Science.

The research was led by Dr. Matthew Ellinwood, a veterinarian and animal science professor at Iowa State University, in collaboration with Dr. Patricia Dickson at the Harbor-UCLA Medical Center, with colleagues at the Iowa State College of Veterinary Medicine, the University of Tennessee, St. Louis University and the University of Pennsylvania. Their work was published in the AAAS journal Science Translational Medicine.

The research focused on a disorder called mucopolysaccharidosis type I, or MPS I, which is caused by the lack of a key enzyme that breaks down substances the body needs to help build normal nerves, bone, cartilage, tendons, corneas, skin and connective tissue.

The researchers demonstrated that beginning replacement of the enzyme shortly after birth prevented irreversible damage caused by the disease. Previous studies on older subjects were only able to reduce MPS I symptoms with enzyme replacement therapy. Especially important was the prevention of clinical signs of brain, heart and bone disease.

"This study, for the first time, outlines the potential to fully treat mucopolysaccharidosis type I using current technology and medicines, and prevent what might otherwise be the fatal or seriously debilitating consequence of this inherited disease," Ellinwood said.

"This study will strengthen the need and demand for neo-natal screening for this rare disorder. Overall, we feel our discoveries outline tremendous improvements for the treatment of these sorts of rare genetic disorders generally and for the treatment of MPS I specifically," said Ellinwood, who has been studying the disease for 12 years in dogs, which also suffer from the disorder.

His past work helped identify a genetic mutation that led to a DNA testing program for the Schipperke dog breed that has for all practical purposes eliminated the disease.

There is no cure for severe forms of MPS I and similar disorders, which are collectively known as lysosomal storage diseases. Symptoms include clouding of eye corneas, skeletal deformities, heart valve disease and severe cognitive impairment and decline.

The research opens the door to improved methods of enzyme delivery in human patients with similar genetic disorders. It also suggests that babies could be tested for MPS I at the same time they are tested for other inherited diseases to determine if they need the enzyme replacement therapy.

"There is a test under development to identify children with MPS I at birth, allowing them access to treatment when it could do the most good. Currently, diagnosis is usually made after clinical signs of disease have already begun, and the rarity of the condition makes pre-natal diagnosis impractical," Ellinwood said.

MPS and related diseases are hereditary and almost without exception they are recessive, with a child receiving one mutant copy of the gene from each parent. Due to the recessive nature of the disease parents are unaffected, and have no way of knowing if they are carriers.


'/>"/>

Contact: Matthew Ellinwood
mellinwo@iastate.edu
515-294-5136
Iowa State University
Source:Eurekalert

Related medicine news :

1. UCSF Enters Drug Discovery Agreement with Genentech
2. UCSF enters drug discovery agreement with Genentech
3. New discovery: Plaice are spotted (on the inside)
4. SeqWright Advances Genomic Discovery With Isilon IQ
5. Effective prostate cancer treatment discovery
6. Co-Creator of Six Sigma Unveils “The Great Discovery” ... the 4th Generation of Six Sigma
7. U discovery gives insight into brain replay process
8. Discovery of cellular switch may provide new means of triggering cell death, treating disease
9. Discovery May Lead to Better Multiple Sclerosis Treatments
10. Astrogenetix Narrows in on MRSA Virulence Onboard Discovery
11. TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, ... stress of modern life continually makes more demands on time and energy, people are ... trap people in vicious high/low cycles and can also cause long term health issues. ...
(Date:8/21/2017)... ... August 22, 2017 , ... Nanoparticle research provides ... and safety. By learning and implementing best practices for containment using ventilated safety ... attendees will gain a better understanding of a method for safely testing nanotechnology ...
(Date:8/21/2017)... MINNEAPOLIS, MINN (PRWEB) , ... August 21, 2017 ... ... Sports Group, today announced that it has become the Official Technology Partner of ... their AES (Advanced Event Systems) volleyball software, along with providing sport ...
(Date:8/21/2017)... , ... August 21, 2017 , ... The experts have ... are we supposed to get things done in a healthy way these days? FlexiSpot, ... launching a crowdfunding campaign on August 28 to introduce Deskcise Pro™– the world’s first ...
(Date:8/21/2017)... CA (PRWEB) , ... August 21, 2017 , ... ... health services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar ... responders affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
Breaking Medicine Technology: